-- According to the report, the global psoriatic arthritis treatment industry was pegged at $7.86 billion in 2018, and is expected to reach $13.74 billion by 2026, growing at a CAGR of 7.2% from 2019 to 2026.
Psoriatic arthritis is a form of arthritis disorder developed in individuals affected by psoriasis. It leads to joint stiffness, pain, and swelling. Most individuals initially develop psoriasis and are later diagnosed with psoriatic arthritis. According to a study published by Celgene Corporation, in 2018, approximately 30% of patients with psoriasis disorder develop inflammatory situation involving joints, known as psoriatic arthritis. Several prescription and over-the-counter (OTC) drugs are available for the treatment of psoriatic arthritis. Some treat symptoms of both psoriatic arthritis and psoriasis, while others help with joint issues. Medications for psoriatic arthritis treatment include NSAIDs, DMARDs, biologics, and others.
This report contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak
Download free Sample Report @ https://www.alliedmarketresearch.com/request-sample/6316
Biologics segment dominated the market
By drug type, the biologics segment held the largest share in 2018, contributing to more than three-fifths of the global psoriatic arthritis treatment market. Moreover, the segment is expected to register the fastest CAGR of 7.9% during the forecast period. This is due to surge in patient awareness toward the availability of DMARDs drugs for psoriatic arthritis treatment, rise in prevalence of psoriatic arthritis, presence of biologics &biosimilars, and increase in healthcare expenditure in developed regions. The report includes an in-depth analysis other segments such as NSAIDs, DMARDs, and other.
North America held the largest share
The global psoriatic arthritis treatment market across North America held the largest share in 2018, contributing for more than half of the market, owing to presence of key players in the region. Moreover, rise in prevalence of psoriatic arthritis disease, surge in demand for psoriatic arthritis treatment drugs, presence of advanced healthcare facilities coupled with trained medical professionals, and surge in number of R&D centers significantly contribute toward the growth of the North America market. However, the Asia-Pacific segment is expected to register the fastest CAGR of 9.1% during the forecast period, owing to high population base, surge in awareness about psoriatic arthritis treatment products, and increase in prevalence of psoriasis & psoriatic arthritis disease in various countries.
Get detailed COVID-19 impact analysis on the Psoriatic Arthritis Treatment Market:
https://www.alliedmarketresearch.com/request-for-customization/6316?reqfor=covid
Major market player
AbbVie Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Eli Lilly And Company
Celgene Corporation
Merck & Co Inc.
Johnson & Johnson
Pfizer Inc.
Novartis AGUCB S.A.
For Purchase Enquiry at:https://www.alliedmarketresearch.com/purchase-enquiry/6316
Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Address: 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States
Phone: 1-800-792-5285
Website: https://www.alliedmarketresearch.com/
Release ID: 89031055
Google
RSS